Refractory asthma is asthma that remains uncontrolled despite maximum standard treatment. It affects roughly 3.6% of all adults with asthma, a number lower than the 5% to 10% that experts long estimated. Unlike ordinary asthma that responds to inhalers and lifestyle changes, refractory asthma persists even when a person is doing everything right: taking medications correctly, avoiding triggers, and managing related health conditions.
How It Differs From Difficult-to-Treat Asthma
The terms “difficult asthma,” “difficult-to-treat asthma,” and “refractory asthma” are often used interchangeably, but they describe different situations. Difficult-to-treat asthma is the broader category. It includes anyone whose asthma stays uncontrolled on high-intensity treatment, but the reasons can be fixable: poor inhaler technique, skipping doses, unmanaged allergies, or conditions like acid reflux making symptoms worse.
Refractory asthma is what remains after all those fixable factors have been ruled out. A joint definition from the European Respiratory Society and American Thoracic Society describes it as asthma that stays uncontrolled despite treatment with high-dose inhaled steroids combined with additional controller medications for at least a year, or asthma that requires oral steroids for at least half the year just to stay partially controlled. In practical terms, refractory asthma is the subset of difficult asthma where the disease itself, not the circumstances around it, is the problem.
Why Standard Medications Stop Working
Inhaled corticosteroids are the backbone of asthma treatment because they suppress airway inflammation. In refractory asthma, the cells lining the airways become resistant to these drugs. This happens through several overlapping mechanisms. The receptors that steroids bind to in order to switch off inflammation can become less active or fail to move into the cell’s nucleus where they do their work. Inflammatory signaling molecules essentially jam the lock that steroids need to open.
One well-studied pathway involves a protein called HDAC2, which steroids rely on to silence inflammatory genes. In people with refractory asthma, HDAC2 levels drop, and the drugs lose their ability to turn off inflammation even at high doses. This reduced HDAC2 activity is linked to more severe disease in both asthma and chronic obstructive pulmonary disease, suggesting a shared mechanism behind steroid resistance in lung conditions.
The Two Main Inflammatory Patterns
Not all refractory asthma looks the same under a microscope. The type of immune cells driving the inflammation determines how the disease behaves and which treatments might help.
The first pattern, called T2-high, is driven by allergic-type immune responses. White blood cells called eosinophils flood the airways, and the immune system overproduces signaling molecules like IL-4, IL-5, and IL-13. This is the pattern most biologic drugs are designed to target, and it tends to respond better to treatment overall.
The second pattern, T2-low, involves neutrophils rather than eosinophils. It is promoted by a different set of immune signals, particularly IL-17, and is more closely associated with steroid resistance. People with T2-low refractory asthma are harder to treat because fewer targeted therapies exist for this pattern. They also tend to have higher rates of hypertension and chronic low-grade inflammation that extends beyond the lungs.
Conditions That Make It Worse
Several coexisting health problems can amplify refractory asthma or mimic its symptoms, making accurate diagnosis harder. Before asthma is labeled refractory, these conditions need to be identified and managed.
- Obesity has a bidirectional relationship with asthma. It increases exacerbation frequency and severity, worsens symptom control, and impairs the response to inhaled steroids. In children, obesity is associated with greater need for emergency interventions.
- Chronic rhinosinusitis, especially with nasal polyps, is an independent risk factor for difficult asthma. It worsens both symptom control and lung function.
- Gastroesophageal reflux disease (GERD) can cause coughing, wheezing, and airway swelling through acid irritation and nerve-triggered airway tightening. These symptoms overlap with asthma flares, sometimes leading to unnecessary increases in asthma medication.
- Obstructive sleep apnea contributes to poor asthma control and more frequent exacerbations in both adults and children.
- Anxiety and depression are associated with worse symptom reporting and quality of life, and can interfere with treatment adherence.
Addressing these conditions won’t cure refractory asthma, but it can reduce the burden on the airways enough to improve daily control and reduce flare-ups.
Biologic Therapies
The biggest shift in refractory asthma treatment over the past decade has been the introduction of biologic drugs. These are injected medications that block specific immune signals fueling airway inflammation. Six biologics are currently available for severe asthma, each targeting a different part of the inflammatory chain:
- Omalizumab blocks IgE, the antibody responsible for allergic reactions. It was the first biologic approved for severe asthma.
- Mepolizumab and reslizumab block IL-5, a signaling molecule that drives eosinophil production.
- Benralizumab targets the IL-5 receptor on eosinophils directly, depleting them more aggressively.
- Dupilumab blocks the receptor for both IL-4 and IL-13, interrupting two major drivers of T2-high inflammation.
- Tezepelumab blocks TSLP, a signaling molecule released by airway cells that sits upstream of multiple inflammatory pathways. It is the first biologic shown to benefit some patients with T2-low asthma as well.
Choosing the right biologic depends on blood and airway biomarkers, particularly eosinophil counts and IgE levels. The ERS/ATS guidelines recommend measuring specific biomarkers before starting any of these therapies, since matching the drug to the patient’s inflammatory pattern significantly affects the outcome. For many people, biologics reduce exacerbations, lower or eliminate the need for oral steroids, and improve quality of life in ways that were not possible a generation ago.
Bronchial Thermoplasty
For people whose refractory asthma does not respond to biologic therapy, or whose inflammation is not driven by the T2-high pathway, bronchial thermoplasty is an option. This procedure uses controlled heat delivered through a flexible scope to reduce the thickened smooth muscle in the airway walls, a structural feature of severe asthma that contributes to airway narrowing.
The procedure is done under general anesthesia in three separate sessions spaced at least three weeks apart. Each session targets a different region of the lungs. Patients typically stay in the hospital overnight after each session. In clinical practice, bronchial thermoplasty has reduced severe exacerbations by 75% and hospital admissions by 38%. It is generally considered for people with persistent symptoms after failing high-dose triple inhaler therapy, particularly those with a non-allergic, non-eosinophilic pattern that biologics are less likely to help.
Living With Refractory Asthma
Refractory asthma affects roughly 10 out of every 10,000 people in the general population. That rarity means it often takes years of trial and error before the diagnosis is confirmed and the right treatment plan is found. Many people cycle through multiple inhalers and oral steroid courses before being referred to a specialist center where biomarker testing and access to biologics are available.
The practical reality of refractory asthma includes frequent exacerbations, limits on physical activity, disrupted sleep, and the cumulative side effects of long-term oral steroid use, including weight gain, bone thinning, and elevated blood sugar. Biologic therapies have changed the trajectory for many patients by reducing steroid dependence, but they require ongoing injections, typically every two to eight weeks depending on the drug, and periodic reassessment to confirm they are still the right fit.